# Pizarra — PT-pseudo_c7277954c60f (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c7277954c60f
Task: 1

Encounter: Urology - outpatient on 18 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 54-year-old male
  - PSA: 9.8 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.073 ng/mL²
  - PSA velocity: 1.0 ng/mL/yr
  - Prior PSA: 8.6 ng/mL
  - Prostate volume: 134.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.5260261 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Obesity (BMI >30)
  - Problem list / PMHx: Obesity (BMI >30)
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 9.8 ng/mL. PI-RADS 2. PSAD 0.07. Prostate volume 134 mL. csPCa 0.53.

Vitals: weight 74 kg, height 176 cm, BMI 23.9, BP 125/82 mmHg, HR 86 bpm. Smoking: Ex-smoker (12 pack-yr, quit 2017).

Chief complaint: Specialist evaluation requested to interpret recent multiparametric imaging results and address a steadily ascending PSA trajectory.

History: At 54 years of age, this retired shopkeeper shares a household with his unmarried partner and seeks re-evaluation for a persistently rising PSA curve. Lower urinary tract complaints are minimal, requiring no drug therapy. Physical activity includes biweekly home weight training, while alcohol consumption remains limited to one unit weekly. Tobacco cessation occurred in 2017 after a 12 pack-year exposure. Vision has progressively worsened over recent years, mandating large-print formats for all clinical documentation. Medical history includes obesity (BMI >30), stable COPD requiring periodic pulmonary function testing, and a recently completed endocrine assessment for thyroid screening. He explicitly denies bone discomfort, haematuria, or unexplained weight loss, maintaining overall stability throughout the diagnostic phase.

Physical examination: Genital assessment unremarkable; per rectum, digital rectal examination confirms a normal DRE. The gland appears symmetrically enlarged with a smooth, rubbery texture, devoid of palpable nodules or asymmetry. Systemic evaluation shows stable vital signs, absent lymphadenopathy, and no indicators of broader illness.

Patient info: retired shopkeeper; Living with partner (unmarried); Lives with partner.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 1 units / week; exercise Light weight-training at home, 2x/week; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up; Endocrine — thyroid screening.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.45 +/- 0.18   (95% CI 0.09-0.81)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.18  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.99 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: DEFER BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 3 or higher lesion?
  - psa_trend (get_psa_trend) -> Does the PSA trajectory warrant immediate intervention?
  - previous_notes (get_previous_notes) -> What is the prior management context and agreed-upon surveillance pathway?

This case hinges on the PI-RADS score from the MRI and the trajectory of the PSA. We must retrieve the imaging report, PSA history, and prior notes to determine if the guideline deferral criterion is met or if the clinical picture demands a biopsy.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which included PSA 9.8 ng/mL, PI-RADS 2, and csPCa probability 0.526. It failed to incorporate the context that the guideline criterion is based on the PI-RADS score (2) being in the deferral range (1-2) and the need to assess the PSA trajectory. It did not account for the specific PSA velocity (1.0 ng/mL/yr) or the patient's history of obesity or COPD, which might influence risk stratification beyond the basic variables used by the model.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.45, which falls into the 'discuss' tier because the epistemic error (0.18) straddles 0.5. This is potentially wrong because the guideline criterion explicitly states to defer biopsy when PI-RADS is 1-2, but the rising PSA trajectory suggests a need for closer scrutiny, which the prior did not weigh sufficiently. The model might be wrong because it failed to recognize that a PI-RADS 2 lesion combined with a rising PSA velocity warrants a different interpretation than a static PI-RADS 2.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 3 or higher lesion?
psa_trend - Does the PSA trajectory warrant immediate intervention?
previous_notes - What is the prior management context and agreed-upon surveillance pathway?
laboratory panel - What are the full laboratory results?

GUIDELINE ANCHOR
The guideline states that biopsy is indicated when the mpMRI shows a PI-RADS 3 or higher lesion, and deferral is recommended when the PI-RADS is 1-2.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: The gland exhibits marked hypertrophy, spanning roughly 5.8 x 5.2 x 4.6 cm and culminating in a total volume of 134.0 mL. Scanning reveals no focal abnormality warranting a PI-RADS 3 or greater classification. Impression: Prostatic hypertrophy (total volume 134.0 mL) lacking a PI-RADS 3+ focus. PI-RADS 2.

get_psa_trend
PSA trend: [{"date": "Jan 2024", "val": 1.1}, {"date": "May 2024", "val": 2.9}, {"date": "Aug 2024", "val": 6.0}, {"date": "Nov 2024", "val": 3.8}, {"date": "Feb 2025", "val": 9.8}]

get_previous_notes
Previous notes: Date: 28 Aug 2023, Author: Dr. E. Mulder (GP), Text: 28 Aug 2023 consultation noted mild urinary hesitancy with minimal patient concern. Initial serum PSA measured 6.1 ng/mL. Subsequent testing in early 2024 demonstrated a progressive upward trend, leading to this current urological referral for comprehensive assessment.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and no information from the retrieved documents raised a specific question requiring this panel.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA trajectory shows a significant rise, culminating in a current PSA of 9.8 ng/mL.

AGAINST sampling this patient now:
- MRI report shows PI-RADS 2, which falls within the deferral range (1-2) according to the protocol.
- Previous notes indicate a history of a progressively rising PSA, but no prior biopsy grade is documented.

WHERE THIS LEANS
The evidence points towards deferral based on the PI-RADS 2 finding, despite the concerning PSA trajectory.
LEAN: defer

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=no, evidence=no.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents (MRI report showing PI-RADS 2 and PSA trend) support the guideline criterion to defer biopsy. The record is sufficient to proceed to the final decision.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: clear)

The decision to defer biopsy is supported by the guideline criterion, as the mpMRI showed a PI-RADS 2, which falls within the deferral range (1-2). Although the PSA trajectory was concerning, the retrieved MRI report confirmed no PI-RADS 3+ lesion. The statistical prior suggested no biopsy, and the evidence converged on deferral based on the imaging finding.

Variables that carried weight: age=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
